Review



primary antibodies for igfbp5  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bioss primary antibodies for igfbp5
    <t>IGFBP5</t> is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01
    Primary Antibodies For Igfbp5, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies for igfbp5/product/Bioss
    Average 94 stars, based on 1 article reviews
    primary antibodies for igfbp5 - by Bioz Stars, 2026-04
    94/100 stars

    Images

    1) Product Images from "Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression"

    Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

    Journal: Discover Oncology

    doi: 10.1007/s12672-025-02390-w

    IGFBP5 is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01
    Figure Legend Snippet: IGFBP5 is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01

    Techniques Used: Expressing, Transfection, Immunohistochemistry, Staining

    miR-103a-3p targets IGFBP5 and inhibits its expression. a The expression of miR-103a-3p was quantified by qRT-PCR after transfection with mimic/inhibitor miR-103a-3p in AGS and MKN45 cells. b The binding sites of miR-103a-3p and IGFBP5 ( top: mutated target sequence of IGFBP5, middle: wt target DNA sequence of IGFBP5, bottom: miRNA sequence). c Luciferase reporter assays were conducted on AGS and MKN45 cells transfected with either miR-103a-3p mimic or control, along with wild-type or mutant IGFBP5 3ʹ-UTR constructs. *p < 0.05, **p < 0.01
    Figure Legend Snippet: miR-103a-3p targets IGFBP5 and inhibits its expression. a The expression of miR-103a-3p was quantified by qRT-PCR after transfection with mimic/inhibitor miR-103a-3p in AGS and MKN45 cells. b The binding sites of miR-103a-3p and IGFBP5 ( top: mutated target sequence of IGFBP5, middle: wt target DNA sequence of IGFBP5, bottom: miRNA sequence). c Luciferase reporter assays were conducted on AGS and MKN45 cells transfected with either miR-103a-3p mimic or control, along with wild-type or mutant IGFBP5 3ʹ-UTR constructs. *p < 0.05, **p < 0.01

    Techniques Used: Expressing, Quantitative RT-PCR, Transfection, Binding Assay, Sequencing, Luciferase, Control, Mutagenesis, Construct

    miR-103a-3p promotes the mRNA and protein expression of GC cell via hampering IGFBP5. IGFBP5 mRNA a and protein b expression after oe IGFBP5 (overexpression of IGFBP5) transfection in AGS and MKN45 cells. c IGFBP5 mRNA expression was assessed in AGS and MKN45 cells using qRT-PCR under different treatment conditions. d western blot examined IGFBP5 protein expression in AGS and MKN45 cells with different treatments. *p < 0.05, **p < 0.01
    Figure Legend Snippet: miR-103a-3p promotes the mRNA and protein expression of GC cell via hampering IGFBP5. IGFBP5 mRNA a and protein b expression after oe IGFBP5 (overexpression of IGFBP5) transfection in AGS and MKN45 cells. c IGFBP5 mRNA expression was assessed in AGS and MKN45 cells using qRT-PCR under different treatment conditions. d western blot examined IGFBP5 protein expression in AGS and MKN45 cells with different treatments. *p < 0.05, **p < 0.01

    Techniques Used: Expressing, Over Expression, Transfection, Quantitative RT-PCR, Western Blot

    miR-103a-3p facilitates the proliferation, migration, and invasion of GC cells by inhibiting IGFBP5. Proliferation capacity was assessed in AGS and MKN45 cells under different treatments using CCK8 a and colony formation b assays. Transwell assays were used to detect the invasion c and migration d abilities of AGS and MKN45 cells under varying treatments
    Figure Legend Snippet: miR-103a-3p facilitates the proliferation, migration, and invasion of GC cells by inhibiting IGFBP5. Proliferation capacity was assessed in AGS and MKN45 cells under different treatments using CCK8 a and colony formation b assays. Transwell assays were used to detect the invasion c and migration d abilities of AGS and MKN45 cells under varying treatments

    Techniques Used: Migration



    Similar Products

    primary antibodies for igfbp5  (Bioss)
    94
    Bioss primary antibodies for igfbp5
    <t>IGFBP5</t> is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01
    Primary Antibodies For Igfbp5, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies for igfbp5/product/Bioss
    Average 94 stars, based on 1 article reviews
    primary antibodies for igfbp5 - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    primary antibodies against igfbp5  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology primary antibodies against igfbp5
    <t>IGFBP5</t> is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01
    Primary Antibodies Against Igfbp5, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against igfbp5/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against igfbp5 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    primary antibodies against igfbp5  (Proteintech)
    93
    Proteintech primary antibodies against igfbp5
    SiRNA and primer sequences.
    Primary Antibodies Against Igfbp5, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against igfbp5/product/Proteintech
    Average 93 stars, based on 1 article reviews
    primary antibodies against igfbp5 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    igfbp5 (1:100) primary antibody for western blot  (Boster Bio)
    90
    Boster Bio igfbp5 (1:100) primary antibody for western blot
    SiRNA and primer sequences.
    Igfbp5 (1:100) Primary Antibody For Western Blot, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igfbp5 (1:100) primary antibody for western blot/product/Boster Bio
    Average 90 stars, based on 1 article reviews
    igfbp5 (1:100) primary antibody for western blot - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    igfbp5 primary antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology igfbp5 primary antibody
    Immunohistochemical staining for IBFBP5 in breast tissue. (A) Low (+), (B) medium (++) and (C) strong (+++) positive cytoplasmic staining for <t>IGFBP5.</t>
    Igfbp5 Primary Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igfbp5 primary antibody/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    igfbp5 primary antibody - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    igfbp5 primary antibodies  (Cayman Chemical)
    90
    Cayman Chemical igfbp5 primary antibodies
    Immunohistochemical staining for IBFBP5 in breast tissue. (A) Low (+), (B) medium (++) and (C) strong (+++) positive cytoplasmic staining for <t>IGFBP5.</t>
    Igfbp5 Primary Antibodies, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igfbp5 primary antibodies/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    igfbp5 primary antibodies - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    IGFBP5 is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01

    Journal: Discover Oncology

    Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

    doi: 10.1007/s12672-025-02390-w

    Figure Lengend Snippet: IGFBP5 is a predicted target of miR-103a-3p. Heatmap a and volcano plot b of differentially expressed genes between untreated GC cells and miR-103a-3p-inhibited GC cells. N = 3 per group. c IGFBP5 expression levels between the NC and miR_IN groups (NC cells and miR inhibitor-transfected cells). d Gene Set Enrichment Analysis of differentially expressed genes in untreated GC cells and miR-103a-3p-inhibited GC cells. e Significant correlation is observed between miR-103a-3p and IGFBP5 expression based on TCGA-STAD. f Immunohistochemistry staining was used to determine the expression level of IGFBP5 in GC tissues and adjacent tissues. The mRNA g and protein h expression of IGFBP5 was detected in GES-1, MKN45, AGS, HGC-27 cells. *p < 0.05, **p < 0.01

    Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

    Techniques: Expressing, Transfection, Immunohistochemistry, Staining

    miR-103a-3p targets IGFBP5 and inhibits its expression. a The expression of miR-103a-3p was quantified by qRT-PCR after transfection with mimic/inhibitor miR-103a-3p in AGS and MKN45 cells. b The binding sites of miR-103a-3p and IGFBP5 ( top: mutated target sequence of IGFBP5, middle: wt target DNA sequence of IGFBP5, bottom: miRNA sequence). c Luciferase reporter assays were conducted on AGS and MKN45 cells transfected with either miR-103a-3p mimic or control, along with wild-type or mutant IGFBP5 3ʹ-UTR constructs. *p < 0.05, **p < 0.01

    Journal: Discover Oncology

    Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

    doi: 10.1007/s12672-025-02390-w

    Figure Lengend Snippet: miR-103a-3p targets IGFBP5 and inhibits its expression. a The expression of miR-103a-3p was quantified by qRT-PCR after transfection with mimic/inhibitor miR-103a-3p in AGS and MKN45 cells. b The binding sites of miR-103a-3p and IGFBP5 ( top: mutated target sequence of IGFBP5, middle: wt target DNA sequence of IGFBP5, bottom: miRNA sequence). c Luciferase reporter assays were conducted on AGS and MKN45 cells transfected with either miR-103a-3p mimic or control, along with wild-type or mutant IGFBP5 3ʹ-UTR constructs. *p < 0.05, **p < 0.01

    Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

    Techniques: Expressing, Quantitative RT-PCR, Transfection, Binding Assay, Sequencing, Luciferase, Control, Mutagenesis, Construct

    miR-103a-3p promotes the mRNA and protein expression of GC cell via hampering IGFBP5. IGFBP5 mRNA a and protein b expression after oe IGFBP5 (overexpression of IGFBP5) transfection in AGS and MKN45 cells. c IGFBP5 mRNA expression was assessed in AGS and MKN45 cells using qRT-PCR under different treatment conditions. d western blot examined IGFBP5 protein expression in AGS and MKN45 cells with different treatments. *p < 0.05, **p < 0.01

    Journal: Discover Oncology

    Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

    doi: 10.1007/s12672-025-02390-w

    Figure Lengend Snippet: miR-103a-3p promotes the mRNA and protein expression of GC cell via hampering IGFBP5. IGFBP5 mRNA a and protein b expression after oe IGFBP5 (overexpression of IGFBP5) transfection in AGS and MKN45 cells. c IGFBP5 mRNA expression was assessed in AGS and MKN45 cells using qRT-PCR under different treatment conditions. d western blot examined IGFBP5 protein expression in AGS and MKN45 cells with different treatments. *p < 0.05, **p < 0.01

    Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

    Techniques: Expressing, Over Expression, Transfection, Quantitative RT-PCR, Western Blot

    miR-103a-3p facilitates the proliferation, migration, and invasion of GC cells by inhibiting IGFBP5. Proliferation capacity was assessed in AGS and MKN45 cells under different treatments using CCK8 a and colony formation b assays. Transwell assays were used to detect the invasion c and migration d abilities of AGS and MKN45 cells under varying treatments

    Journal: Discover Oncology

    Article Title: Targeting miR-103a-3p/IGFBP5 axis: a potential therapeutic strategy for gastric cancer progression

    doi: 10.1007/s12672-025-02390-w

    Figure Lengend Snippet: miR-103a-3p facilitates the proliferation, migration, and invasion of GC cells by inhibiting IGFBP5. Proliferation capacity was assessed in AGS and MKN45 cells under different treatments using CCK8 a and colony formation b assays. Transwell assays were used to detect the invasion c and migration d abilities of AGS and MKN45 cells under varying treatments

    Article Snippet: The commercial antibodies provided by Bioss included primary antibodies for IGFBP5 (1:1000) and β-actin (1:10,000), as well as a secondary antibody Goat Anti-Rabbit lgG (1:20,000).

    Techniques: Migration

    SiRNA and primer sequences.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: SiRNA and primer sequences.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques:

    Expression of IGFBP5 in KIRP patient. (a) Expression of IGFBP5 in KIRP based on sample type. IGFBP5 is down expressed in KIRP compared with normal controls ( P < 0.001). (b) Expression of IGFBP5 in KIRP based on age. The expression of IGFBP5 in each age subgroup has significance with normal group. (c) Expression of IGFBP5 in KIRP based on gender. The expression of IGFBP5 in each gender subgroup has significant with normal group, but there is no significance between male and female KIRP patients. (d) Expression of IGFBP5 in KIRP based on race. (e) Expression of IGFBP5 in KIRP based on cancer stage. (f) Expression of IGFBP5 in KIRP based on histologic subtype. KIRP = kidney renal papillary renal cell carcinoma.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: Expression of IGFBP5 in KIRP patient. (a) Expression of IGFBP5 in KIRP based on sample type. IGFBP5 is down expressed in KIRP compared with normal controls ( P < 0.001). (b) Expression of IGFBP5 in KIRP based on age. The expression of IGFBP5 in each age subgroup has significance with normal group. (c) Expression of IGFBP5 in KIRP based on gender. The expression of IGFBP5 in each gender subgroup has significant with normal group, but there is no significance between male and female KIRP patients. (d) Expression of IGFBP5 in KIRP based on race. (e) Expression of IGFBP5 in KIRP based on cancer stage. (f) Expression of IGFBP5 in KIRP based on histologic subtype. KIRP = kidney renal papillary renal cell carcinoma.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing

    Survival curve of IGFBP5 and its related genes. (a) Kaplan-Meier survival curve of IGFBP5 for KIRP patients. The cut off value is 36.07. (b) Kaplan-Meier survival curve of VEGFA for KIRP patients. The cut off value is 6.34. (c) Expression of IGFBP5 in KIRP based on sample type. VEGFA is down expressed in KIRP compared with normal controls ( P < 0.05) (d) Kaplan-Meier survival curve of TGF- β for KIRP patients. The cut off value is 6.34.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: Survival curve of IGFBP5 and its related genes. (a) Kaplan-Meier survival curve of IGFBP5 for KIRP patients. The cut off value is 36.07. (b) Kaplan-Meier survival curve of VEGFA for KIRP patients. The cut off value is 6.34. (c) Expression of IGFBP5 in KIRP based on sample type. VEGFA is down expressed in KIRP compared with normal controls ( P < 0.05) (d) Kaplan-Meier survival curve of TGF- β for KIRP patients. The cut off value is 6.34.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing

    IGFBP5 related genes with a Pearson correlation coefficient ≥0.7.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: IGFBP5 related genes with a Pearson correlation coefficient ≥0.7.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques:

    GO and PPI analysis of IGFBP5 related genes. (a) Main GO biological processes for IGFBP5 and its related genes analyzed by Metascape analysis tools. (b) The PPI networks determined by function cluster analysis. Different color represents for different function cluster. (c) The PPI networks determined by function cluster analysis. Different color represents for different P value. GO=gene oncology. PPI = protein-protein interaction.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: GO and PPI analysis of IGFBP5 related genes. (a) Main GO biological processes for IGFBP5 and its related genes analyzed by Metascape analysis tools. (b) The PPI networks determined by function cluster analysis. Different color represents for different function cluster. (c) The PPI networks determined by function cluster analysis. Different color represents for different P value. GO=gene oncology. PPI = protein-protein interaction.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques:

    IGFBP5 expression in human kidney tissue. (a) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by Western blotting. (b) Semiquantitative analysis of IGFBP5 expression in (a) by ImageJ. (c) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by qPCR.

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: IGFBP5 expression in human kidney tissue. (a) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by Western blotting. (b) Semiquantitative analysis of IGFBP5 expression in (a) by ImageJ. (c) IGFBP5 expression in carcinoma tissues compared with paracarcinoma tissues detected by qPCR.

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing, Western Blot

    Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).

    Journal: BioMed Research International

    Article Title: Insulin-Like Growth Factor Binding Protein 5—A Probable Target of Kidney Renal Papillary Renal Cell Carcinoma

    doi: 10.1155/2019/3210324

    Figure Lengend Snippet: Expression of IGFBP5 in Caki-2 cell line. (a) Expression of VEGFA after inhibited by siRNA ( n = 3). The fold change is 3.1 ( P < 0.01). (b) Expression of TGF- β after inhibited by siRNA ( n = 3). The fold change is 5.4 ( P < 0.01). (c) Expression of IGFBP5 after VEGFA and TGF- β blocked by siRNA ( n = 3). IGFBP5 was downregulated by 2.6-fold and 4.0 fold respectively ( P < 0.01). (d) Expression of IGFBP5 after stimulated by VEGF 165 and TGF- β ( n = 3). IGFBP5 was upregulated by 2.8-fold and 6.2-fold respectively ( P < 0.01). (e) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of IGFBP5 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of IGFBP5 knockdown group is lower than normal control group ( P < 0.05). (f) Cell proliferation rate of Caki-2 detected by MTT assay ( n = 3). The proliferation rate of VEGF 165 stimulation group is higher than normal control group ( P < 0.05), and cell proliferation of TGF- β stimulation group is lower than normal control group ( P < 0.05). ( n = 3) (∗, p < 0.05;∗∗, p < 0.01;∗∗∗, p < 0.001).

    Article Snippet: The following antibodies were used for Western blotting: primary antibodies against IGFBP5 (Proteintech, 55205-1-AP, rab) and GAPDH (CST, 2118, rab) and a goat anti-rab IgG-HRP secondary antibody (Beyotime, A0208).

    Techniques: Expressing, MTT Assay, Control, Knockdown

    Immunohistochemical staining for IBFBP5 in breast tissue. (A) Low (+), (B) medium (++) and (C) strong (+++) positive cytoplasmic staining for IGFBP5.

    Journal: Genetics and Molecular Biology

    Article Title: Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5

    doi: 10.1590/S1415-475738120140167

    Figure Lengend Snippet: Immunohistochemical staining for IBFBP5 in breast tissue. (A) Low (+), (B) medium (++) and (C) strong (+++) positive cytoplasmic staining for IGFBP5.

    Article Snippet: After deparaffinization and antibody retrieval, tissue sections were incubated overnight with IGFBP5 primary antibody (antibody C-18, diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with phosphate-buffered saline (PBS) and incubated with secondary antibody for 30 min. IGFBP5 protein was visualized using streptavidin-HRP and diaminobenzidine (DAB).

    Techniques: Immunohistochemical staining, Staining

    miR-140-5p and miR-193b expression in invasive breast carcinomas in relation to clinicopathological characteristics and IGFBP5 expression

    Journal: Genetics and Molecular Biology

    Article Title: Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5

    doi: 10.1590/S1415-475738120140167

    Figure Lengend Snippet: miR-140-5p and miR-193b expression in invasive breast carcinomas in relation to clinicopathological characteristics and IGFBP5 expression

    Article Snippet: After deparaffinization and antibody retrieval, tissue sections were incubated overnight with IGFBP5 primary antibody (antibody C-18, diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with phosphate-buffered saline (PBS) and incubated with secondary antibody for 30 min. IGFBP5 protein was visualized using streptavidin-HRP and diaminobenzidine (DAB).

    Techniques: Expressing, Immunohistochemistry

    Patient demographics and tumor characteristics.

    Journal: Genetics and Molecular Biology

    Article Title: Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5

    doi: 10.1590/S1415-475738120140167

    Figure Lengend Snippet: Patient demographics and tumor characteristics.

    Article Snippet: After deparaffinization and antibody retrieval, tissue sections were incubated overnight with IGFBP5 primary antibody (antibody C-18, diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with phosphate-buffered saline (PBS) and incubated with secondary antibody for 30 min. IGFBP5 protein was visualized using streptavidin-HRP and diaminobenzidine (DAB).

    Techniques:

    miR-140-5p expression in tissues with positive and negative immunohistochemical staining for IGFBP5. Of the 80 samples analyzed immunohistochemically, those that were IGFBP5-negative showed significantly greater miR-140-5p expression than IGFBP5-positive samples (p = 0.009; Mann-Whitney U-test); miR-140 expression is 4-fold less than in tissues that do not express IGFBP5 protein. The numbers beside some of the asterisks (*) states the sample number. The error bars indicate the 95% confidence intervals (CI).

    Journal: Genetics and Molecular Biology

    Article Title: Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5

    doi: 10.1590/S1415-475738120140167

    Figure Lengend Snippet: miR-140-5p expression in tissues with positive and negative immunohistochemical staining for IGFBP5. Of the 80 samples analyzed immunohistochemically, those that were IGFBP5-negative showed significantly greater miR-140-5p expression than IGFBP5-positive samples (p = 0.009; Mann-Whitney U-test); miR-140 expression is 4-fold less than in tissues that do not express IGFBP5 protein. The numbers beside some of the asterisks (*) states the sample number. The error bars indicate the 95% confidence intervals (CI).

    Article Snippet: After deparaffinization and antibody retrieval, tissue sections were incubated overnight with IGFBP5 primary antibody (antibody C-18, diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with phosphate-buffered saline (PBS) and incubated with secondary antibody for 30 min. IGFBP5 protein was visualized using streptavidin-HRP and diaminobenzidine (DAB).

    Techniques: Expressing, Immunohistochemical staining, Staining, MANN-WHITNEY

    Correlation between IGFBP5 mRNA (RT-PCR) and protein (immunohistochemistry - IHC) expression levels.

    Journal: Genetics and Molecular Biology

    Article Title: Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5

    doi: 10.1590/S1415-475738120140167

    Figure Lengend Snippet: Correlation between IGFBP5 mRNA (RT-PCR) and protein (immunohistochemistry - IHC) expression levels.

    Article Snippet: After deparaffinization and antibody retrieval, tissue sections were incubated overnight with IGFBP5 primary antibody (antibody C-18, diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), washed with phosphate-buffered saline (PBS) and incubated with secondary antibody for 30 min. IGFBP5 protein was visualized using streptavidin-HRP and diaminobenzidine (DAB).

    Techniques: Immunohistochemistry, Expressing